Presentation is loading. Please wait.

Presentation is loading. Please wait.

For related symptoms: AVP-786 (agitation): NMDA receptor antagonist

Similar presentations


Presentation on theme: "For related symptoms: AVP-786 (agitation): NMDA receptor antagonist"— Presentation transcript:

1 Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Registration Trials)
For related symptoms: AVP-786 (agitation): NMDA receptor antagonist Avanir Pharmaceuticals AXS-05 (agitation): combination of bupropion (NDRI) and dextromethorphan (NMDA receptor antagonist Axsome Therapeutics Bupriopion (agitation): norepinephrine and dopamine reuptake inhibitor ITI-007 (agitation): 5-HT2A receptor antagonist Intra-Cellular Therapies Pimavanserin (psychosis): selective inverse agonist of serotonin 5- HT2A receptor Acadia Pharmaceuticals Suvorexant (Belsomra®) (sleep): orexin receptor antagonist Merck Sharp & Dohme Aducanumab: amyloid antibody Biogen Albumin + Immunoglobulin: treats primary immunodeficiency Grifols Biologicals ALZT-OP1: Mast cell stabilizer + antiinflammatory AZTherapies Azeliragon: Inhibits receptor for advanced glycation endproducts vTv Therapeutics CAD-106: amyloid vaccine Novartis CNP520: BACE inhibitor Crenezumab: amyloid antibody Hoffmann-La Roche Elenbecestat (E2609): BACE inhibitor Eisai, Biogen Gantenerumab: amyloid antibody Intepiridine (RVT-101): serotonin receptor antagonist Axovant JNJ : BACE inhibitor Janssen Research & Development Lanabecestat (LY , AZD3293): BACE inhibitor Eli Lilly, AstraZeneca MB2 (TRx0237, Methylene Blue): tau aggregation inhibitor TauRx Therapeutics Ltd Sodium oligo-mannurarate (GV-971): inhibits beta-amyloid aggregation Shanghai Greenvalley Pharmaceuticals Solanezumab: amyloid antibody Eli Lilly As of 04/2018

2 Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Academic Trials)
Candesartan: Angiotensin receptor blocker Ihab M. Hajjar, Emory University Curcumin: nutritional supplement University of Florida Exenetide (Exendin-4): improves insulin sensitivity Azienda Ospedaliero-Universitaria di Parma Gantenerumab: amyloid antibody Washington University School of Medicine, Hoffmann-La Roche Ginkgo biloba (with or without donepezil): nutritional supplement First Affiliated Hospital with Nanjing Medical University Guanfacine: α2A receptor agonist Imperial College London Human neural stem cells: pluripotent cell line Second Affiliated Hospital of Soochow University Icosapent Ethyl/ Omega-3 fatty acid: nutritional VA Office of Research and Development Insulin (intranasal): Hormone controlling blood sugar University of Southern California Lisinopril: Angiotensin receptor blocker Ihab M. Hajjar, Emory University Losartan, Amlodipine & Atorvastatin combination therapy: blood pressure reducers University of Texas Southwestern Medical Center Octohydroaminoacridine Succinate: acetylcholinesterase inhibitor Shanghai Mental Health Center Vitamin D: nutritional supplement University Hospital, Tours For related symptoms: Carbamazepine (agitation): voltage-gated sodium channel blocker University of Sussex Escitalopram (agitation): selective serotonin reuptake inhibitor (SSRI) Johns Hopkins School of Public Health Center for Clinical Trials Escitalopram (alone or with Memantine): selective serotonin reuptake inhibitor (SSRI) (Depression) University of California, Los Angeles Methylphenidate: norepinephrine–dopamine reuptake inhibitor (NDRI) (Apathy) Johns Hopkins Bloomberg School of Public Health Mirtazapine (agitation): atypical antidepressant University of Sussex Nabilone/ Dronabinol (agitation): synthetic cannabinoid Sunnybrook Health Sciences Centre Zolpidem (sleep): Short-acting nonbenzodiazepine Brasilia University Hospital Zoplicone (sleep): Nonhypnotic sleep aid As of 04/2018


Download ppt "For related symptoms: AVP-786 (agitation): NMDA receptor antagonist"

Similar presentations


Ads by Google